Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

February 25, 2027

Study Completion Date

February 25, 2027

Conditions

Relapsed and Refractory Multiple Myeloma (RRMM)

Trial Locations (1)

Pfizer, Tokyo